GLP-1 Drugs: What Happens When You Stop Taking Them?

As injectable weight-loss drugs surge in popularity, one question has remained in the spotlight: what happens when patients stop taking them? Even as concerns about significant weight regain have been common, a recent analysis from the Cleveland Clinic has provided a more nuanced answer.

A Nuanced Look at GLP-1 Discontinuation

Studying nearly 8,000 patients, researchers found that many people who discontinued widely used GLP-1 drugs (commonly sold as Wegovy or Zepbound) did not experience dramatic weight regain over the following year. The findings, published in Diabetes, Obesity and Metabolism, suggest that real-world outcomes may differ from earlier clinical trials, which showed patients regaining more than half of their lost weight within 12 months of stopping treatment.

GLP-1 Drugs and Obesity Care: A Changing Landscape

GLP-1 drugs such as semaglutide and tirzepatide have transformed obesity care in recent years, helping patients achieve substantial weight loss. However, most clinical trials assume patients stop treatment without switching to alternatives, a scenario that rarely reflects real-life experiences.

“Many patients who stop these medications either restart them or move to another treatment,” said Hamlet Gasoyan, a researcher with Cleveland Clinic’s Center for Value-Based Care Research who led the study. “That may explain why we see less weight regain than expected.”

Study Details: Tracking Weight Changes After Discontinuation

The research tracked 7,938 adults in Ohio and Florida who had taken semaglutide or tirzepatide for obesity or type 2 diabetes but stopped within three to 12 months. Before discontinuing treatment, patients experienced significant weight loss. Those using the drugs for obesity lost an average of 8.4% of their body weight, while those with diabetes lost 4.4%.

What the Data Showed: A Mixed, But Not Entirely Negative, Picture

A year after stopping, the picture was mixed, but not uniformly negative. Patients in the obesity group regained just 0.5% of body weight on average, while those in the diabetes group continued to lose weight slightly. Importantly, outcomes varied.

• Just over half of patients treated for obesity gained some weight, but 45% either maintained their weight or continued to lose.
• Among those with diabetes, more than half saw stable or further weight loss.

Treatment Transitions After Stopping GLP-1s

many patients in both groups explored other weight-management treatment options within 12 months of stopping their initial GLP-1 injectable:

• 27% switched to a different medication (including older-generation obesity medications or switching between semaglutide and tirzepatide)
• 20% restarted their original medication
• 14% continued their obesity treatment via lifestyle modification visits with healthcare professionals such as dietitians or exercise specialists.
• Less than 1% transitioned to undergoing metabolic and bariatric surgery.

Why Patients Stop and What They Do Next

Cost emerged as the biggest reason patients discontinued treatment, followed by side effects. Insurance coverage also played a role, particularly in determining whether patients restarted therapy. Rather than abandoning treatment altogether, many patients explored other options.

A Long-Term Approach to Obesity Care

The findings highlight a shift in how obesity treatment is understood – not as a single intervention, but as an ongoing process that may involve multiple approaches over time. Researchers say the results underline the importance of continued support, even when patients stop medication. For many, stopping a drug does not indicate the end of treatment, but rather a transition to a different strategy.

As the use of GLP-1 drugs continues to expand, the study offers a reassuring message: while weight regain remains a risk, it is not inevitable, especially when patients remain engaged in their care.